7LAB image
Entry Detail
PDB ID:
7LAB
EMDB ID:
Title:
Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1052
Biological Source:
PDB Version:
Deposition Date:
2021-01-06
Release Date:
2021-03-10
Method Details:
Experimental Method:
Resolution:
2.97 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Spike glycoprotein
Chain IDs:E (auth: A), F (auth: B), G (auth: C)
Chain Length:1121
Number of Molecules:3
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Description:DH1052 light chain
Chain IDs:A (auth: X), C (auth: S), I (auth: L)
Chain Length:199
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:DH1052 heavy chain
Chain IDs:B (auth: Y), D (auth: T), H
Chain Length:227
Number of Molecules:3
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
Li, D, Edwards, R.J, Manne, K, Martinez, D.R, Schafer, A, Alam, S.M, Wiehe, K, Lu, X, Parks, R, Sutherland, L.L, Oguin 3rd, T.H, McDanal, C, Perez, L.G, Mansouri, K, Gobeil, S.M.C, Janowska, K, Stalls, V, Kopp, M, Cai, F, Lee, E, Foulger, A, Hernandez, G.E, Sanzone, A, Tilahun, K, Jiang, C, Tse, L.V, Bock, K.W, Minai, M, Nagata, B.M, Cronin, K, Gee-Lai, V, Deyton, M, Barr, M, Von Holle, T, Macintyre, A.N, Stover, E, Feldman, J, Hauser, B.M, Caradonna, T.M, Scobey, T.D, Rountree, W, Wang, Y, Moody, M.A, Cain, D.W, DeMarco, C.T, Denny, T.N, Woods, C.W, Petzold, E.W, Schmidt, A.G, Teng, I.T, Zhou, T, Kwong, P.D, Mascola, J.R, Graham, B.S, Moore, I.N, Seder, R, Andersen, H, Lewis, M.G, Montefiori, D.C, Sempowski, G.D, Baric, R.S, Acharya, P, Haynes, B.F, Saunders, K.O, Li, D, Edwards, R.J, Manne, K, Martinez, D.R, Schafer, A, Alam, S.M, Wiehe, K, Lu, X, Parks, R, Sutherland, L.L, Oguin, T.H, McDanal, C, Perez, L.G, Mansouri, K, Gobeil, S.M.C, Janowska, K, Stalls, V, Kopp, M, Cai, F, Lee, E, Foulger, A, Hernandez, G.E, Sanzone, A, Tilahun, K, Jiang, C, Tse, L.V, Bock, K.W, Minai, M, Nagata, B.M, Cronin, K, Gee-Lai, V, Deyton, M, Barr, M, Von Holle, T, Macintyre, A.N, Stover, E, Feldman, J, Hauser, B.M, Caradonna, T.M, Scobey, T.D, Moody, M.A, Cain, D.W, DeMarco, C.T, Denny, T.N, Woods, C.W, Petzold, E.W, Schmidt, A.G, Teng, I.T, Zhou, T, Kwong, P.D, Mascola, J.R, Graham, B.S, Moore, I.N, Seder, R, Andersen, H, Lewis, M.G, Montefiori, D.C, Sempowski, G.D, Baric, R.S, Acharya, P, Haynes, B.F, Saunders, K.O.Show
Cell 184 4203 ? (2021)
PMID: 34242577 DOI: 10.1016/j.cell.2021.06.021

Abstact

SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) or the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-γ (FcγR)-mediated enhancement of virus infection in vitro, while five non-neutralizing NTD antibodies mediated FcγR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Three of 46 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated bronchoalveolar lavage inflammatory cytokines. Thus, while in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo, increased lung inflammation can rarely occur in SARS-CoV-2 antibody-infused macaques.

Legend

Protein

Chemical

Disease

Primary Citation of related structures